We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Multi-Matrix COVID-19 Test Could Detect SARS-CoV-2 Days Before Symptoms Appear

By LabMedica International staff writers
Posted on 17 Dec 2020
A new multi-matrix COVID-19 test based on ultra-sensitive technology will be able to detect the SARS-CoV-2 virus in its earliest stages, days before symptoms appear, thus filling the urgent need for asymptomatic screening.

Quanterix (Billerica, MA, USA) plans to file Emergency Use Authorizations (EUAs) for its assays involving multiple COVID-related biomarkers, based on its Simoa technology. More...
Quanterix' proprietary Simoa technology is based on the isolation of individual immunocomplexes on paramagnetic beads using standard ELISA reagents. It gives researchers the ability to closely examine critical biomarkers, enabling the development of methods providing much earlier disease detection, better prognoses and enhanced treatment methods.

Currently, the Quanterix Simoa technology enables researchers to measure baseline levels of important cytokines and chemokines (such as IL-6, TNFα, IL-8 and even low abundance IFNα and IL1β) well above limits of quantification and directly in blood. Measuring early levels of these biomarkers during acute infection can deepen the understanding of cytokine storm onset and related cardiopulmonary and neurological damage. Simoa allows measurement of trace levels of IFNα, which enables separation of bacterial from viral infections, characterization of lupus samples and now following COVID-19 patients IFNα profile and assess type I interferon treatment options.

Quanterix’s newest COVID-19 assay based on its ultra-sensitive Simoa technology is currently being used as a lab-developed test at CLIA labs pending the FDA’s consideration of the company’s EUA application. Quanterix has received a funding of USD 18.2 million from the National Institutes of Health (NIH) to accelerate the continued development, scale-up and deployment of its novel SARS-CoV-2 antigen test based on its ultra-sensitive Simoa technology. The phase 2 contract supports the test's clinical validation in preparation for emergency use authorization submissions with the US Food and Drug Administration. Preliminary results showed the test has the potential to enable the detection of SARS-CoV-2 from sample types, including self-collected capillary blood, saliva and nasal swabs. The contract provides funding to expand assay kit manufacturing capacity and commercial deployment readiness. Utilizing the company’s high-throughput automated HD-X instrument platform, Quanterix intends to make the test available through a network of centralized third-party labs.

Related Links:
Quanterix


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Portable Electronic Pipette
Mini 96
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
Automatic Chemiluminescence Immunoassay Analyzer
Shine i2000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Colorectal cancer under the microscope (Photo courtesy of Adobe Stock)

Unique Microbial Fingerprint to Improve Diagnosis of Colorectal Cancer

Colorectal cancer is the fourth most common cancer in the UK and the second deadliest. New research has revealed that it carries a unique microbial fingerprint, which could help doctors better understand... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.